Overview

Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

Status:
RECRUITING

Trial end date:
2030-10-29

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate whether zilebesiran versus placebo reduces the risk of cardiovascular (CV) death, nonfatal myocardial infarction (MI), nonfatal stroke, or heart failure (HF) events. This is an event-driven study that will continue until the targeted number of positively adjudicated primary endpoint clinical outcome events (COEs) have been reached.

Phase:

PHASE3

Details

Lead Sponsor:

Alnylam Pharmaceuticals

Collaborator:

Hoffmann-La Roche